CASP3 and urinary bladder carcinoma: CB2 activation led to ceramide-mediated bladder cancer cell apoptosis [9,10] and treatment of bladder cancer cells with CB2 agonists induced caspase 3-activation [12], adding credence to the suggestion that cannabinoids act, directly or indirectly, via the CB2 receptor in these cells to induce programmed cell death.